Zerenex To Be Positioned As Cost-Saving, Oral Alternative In ESRD Setting
This article was originally published in The Pink Sheet Daily
Executive Summary
Keryx plans to file an NDA for phosphate binder Zerenex during the second quarter, with an EU filing to follow by mid-year. In a long-term Phase III study, the candidate met its primary efficacy endpoint as well as several secondary endpoints.